# Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

> **NCT05126849** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 31 (estimated)

## Conditions studied

- Refractory Idiopathic Aplastic Anemia
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

## Interventions

- **OTHER:** Allogenic transplantation

## Key facts

- **NCT ID:** NCT05126849
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-06
- **Primary completion:** 2027-01-06
- **Final completion:** 2027-01-06
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05126849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05126849, "Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05126849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*